VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News: Artimplant (STO:ARTIB) is taking its first step towards treatment of spinal disorders with its proprietary biomaterial Artelon®. An Artelon® implant will now be used for investigational treatment of osteoarthritis of the lumbar facet joints. The investigator, Schulthess Clinic Spine Center, plans to start enrolling patients during the second quarter of 2009.
